Third Harmonic Bio Announces Second Quarter 2023 Financial Results
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of…
News
Third Harmonic Bio Announces Second Quarter 2023 Financial Results
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of…
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
AUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
AUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
Prior Approval Supplement (PAS) for VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® assigned a Prescription…
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
Prior Approval Supplement (PAS) for VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® assigned a Prescription…
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper…
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper…
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company)…
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company)…
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595,…
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595,…
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a…
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a…
Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to…
Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to…
Recce Pharmaceuticals Provides Positive Update on Patients Treated with RECCE® 327 Under “Special Access Scheme”
Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure…
Recce Pharmaceuticals Provides Positive Update on Patients Treated with RECCE® 327 Under “Special Access Scheme”
Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure…
Spectral Medical Announces Second Quarter Results and Provides Corporate Update
Tigris Trial Enrollment Reaches 71 Patients TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Spectral Medical…
Spectral Medical Announces Second Quarter Results and Provides Corporate Update
Tigris Trial Enrollment Reaches 71 Patients TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Spectral Medical…